Midwest Professional Planners LTD. Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Midwest Professional Planners LTD. lifted its stake in Exact Sciences Co. (NASDAQ:EXAS) by 16.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,397 shares of the medical research company’s stock after purchasing an additional 613 shares during the quarter. Midwest Professional Planners LTD.’s holdings in Exact Sciences were worth $247,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of EXAS. Atria Investments Inc bought a new stake in Exact Sciences in the 3rd quarter worth about $244,000. Axxcess Wealth Management LLC bought a new stake in Exact Sciences in the 3rd quarter worth about $243,000. Huntington National Bank increased its holdings in Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after buying an additional 352 shares in the last quarter. Curi RMB Capital LLC increased its holdings in Exact Sciences by 3.2% in the 3rd quarter. Curi RMB Capital LLC now owns 24,468 shares of the medical research company’s stock worth $1,667,000 after buying an additional 754 shares in the last quarter. Finally, Metis Global Partners LLC bought a new stake in Exact Sciences in the 3rd quarter worth about $241,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Up 4.6 %

NASDAQ EXAS opened at $45.00 on Friday. The stock’s 50 day moving average is $51.73 and its 200 day moving average is $58.85. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The stock has a market cap of $8.36 billion, a PE ratio of -8.08 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Research analysts predict that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Royal Bank of Canada initiated coverage on Exact Sciences in a report on Thursday. They issued a “sector perform” rating and a $52.00 price objective for the company. BTIG Research boosted their price target on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Benchmark restated a “buy” rating and set a $65.00 price target on shares of Exact Sciences in a research note on Monday, January 13th. Bank of America cut their price target on Exact Sciences from $72.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Finally, Barclays cut their price target on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $70.83.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.